Fairvalue-Calculator Fairvalue-Calculator
EN DE

AP Biosciences, Inc (6945) Fair Value & Analysis

Healthcare · TW · Market cap 9.7B TWD

Price100.00 TWD
Fair Value39.32 TWD
Upside-60.7%
Quality95/100
Evidence: Low Range 29.49 TWD – 49.14 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

AP Biosciences, Inc (6945) currently trades at 100.00 TWD, while our model-based Fair Value estimate is 39.32 TWD — implying the stock looks roughly 60.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. It caters to healthcare and biotechnology industries. AP Biosciences, Inc. has strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. The company was founded in 2013 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is AP Biosciences, Inc (6945) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 39.32 TWD versus a price of 100.00 TWD — about −61% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6945?
Our 21-model fair value for AP Biosciences, Inc is 39.32 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 100.00 TWD.
What is the quality score of 6945?
AP Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.